Cumberland Pharmaceuticals (CPIX) Other Accumulated Expenses (2010 - 2026)

Cumberland Pharmaceuticals has reported Other Accumulated Expenses for 17 years, with the latest figure at $13.0 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 15.67% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 15.67% YoY) and the FY2025 annual result came in at $12.6 million, up 3.14% from the prior year.
• Other Accumulated Expenses climbed to $13.0 million in Q1 2026 per CPIX's latest filing, from $12.6 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $17.6 million in Q4 2022 and troughed at $10.1 million in Q3 2025.
• A 5-year average of $13.1 million and a median of $13.0 million in 2026 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses surged 102.9% in 2022, then dropped 24.51% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $17.6 million in 2022, then declined by 22.69% to $13.6 million in 2023, then fell by 9.9% to $12.3 million in 2024, then climbed by 3.14% to $12.6 million in 2025, then climbed by 2.72% to $13.0 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $13.0 million, $12.6 million, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.